Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2013 | 01:06pm CEST
   By Saabira Chaudhuri 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
04/25DJNasdaq Composite Tops 6000 for First Time
04/25 BIOGEN : Reports First Quarter 2017 Revenues of $2.8 Billion
04/24 BIOGEN : TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early M..
04/21 BIOGEN : SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment..
04/18 BIOGEN : Highlights Advances from Its Neurology Research Programs and Portfolio ..
03/28 BIOGEN : to Present Data at the 13th International Conference on Alzheimer&rsquo..
03/27 BIOGEN : to Report First Quarter 2017 Financial Results on April 25, 2017
03/16 BIOGEN : Appoints Anirvan Ghosh Senior Vice President, Research and Early Develo..
03/01 BIOGEN : Biotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel..
02/28 BIOGEN : to Present at the Cowen & Company 37th Annual Health Care Conference
More news
Sector news : Biopharmaceuticals
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Biopharmaceuticals
News from SeekingAlpha
04/28 How Low Can You Go? U.S. Pharma Already Shoulders Light Tax Burden
04/28 INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apo, tbk, ns, iff, adx, plse
04/27 Amgen's Q1 Shows Challenges And Growth Opportunities Aplenty
04/27 Biogen's Spinraza Dazzles But Rivals Rally
04/26 BIOTECH FORUM DAILY DIGEST : Biogen Kicks Off Earning Season In Style - Spotligh..
Financials ($)
Sales 2017 11 382 M
EBIT 2017 5 846 M
Net income 2017 3 698 M
Finance 2017 258 M
Yield 2017 -
P/E ratio 2017 15,97
P/E ratio 2018 12,98
EV / Sales 2017 5,03x
EV / Sales 2018 4,55x
Capitalization 57 528 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 314 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC3.78%57 528
CSL LIMITED30.36%44 939
GRIFOLS SA30.88%17 025
More Results